MaxCyte Inc (MXCT)vsStryker Corporation (SYK)
MXCT
MaxCyte Inc
$0.84
-3.24%
HEALTHCARE · Cap: $90.34M
SYK
Stryker Corporation
$285.47
-2.98%
HEALTHCARE · Cap: $112.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 76415% more annual revenue ($25.27B vs $33.03M). SYK leads profitability with a 13.2% profit margin vs -135.1%. SYK earns a higher WallStSmart Score of 59/100 (C).
MXCT
Avoid30
out of 100
Grade: F
SYK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.7%
Fair Value
$1.32
Current Price
$0.84
$0.48 discount
Margin of Safety
-7.6%
Fair Value
$265.38
Current Price
$285.47
$20.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -23.6% — below average capital efficiency
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MXCT profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.57 — expect wider price swings.
SYK is growing revenue faster at 2.6% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (59/100 vs 30/100). MXCT offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?